GH SecretagoguesLimited ResearchResearch Only — Preclinical Evidence

IGF-1 DES

des(1-3)IGF-1 / Truncated IGF-1 · IGF-1 receptor (IGF1R) agonism with markedly reduced IGFBP sequestration; activates PI3K/Akt/mTOR and MAPK pathways for protein synthesis and cell proliferation; short free-peptide half-life favors brief, localized signaling rather than sustained systemic exposure

Not medical advice. For educational and research reference only.

Typical Dose

50–150 mcg daily in research discussions (often peri-workout); no established human dose

Route

Injectable (SubQ or IM)

Cycle

Short research cycles only; washouts recommended due to glucose effects

Storage

Lyophilized frozen; reconstituted 2–8°C, use within 2–4 weeks

What is IGF-1 DES?

IGF-1 DES (des(1-3)IGF-1) is a truncated 67-amino-acid analog of insulin-like growth factor-1 missing the N-terminal Gly-Pro-Glu tripeptide. Reduced IGF-binding protein affinity leaves more free peptide for IGF-1 receptor activation, yielding roughly 2–10× potency vs native IGF-1 in preclinical assays — but a very short ~20–30 minute half-life. Evidence is almost entirely animal/cell literature; not FDA-approved.

Mechanism of Action

IGF-1 receptor (IGF1R) agonism with markedly reduced IGFBP sequestration; activates PI3K/Akt/mTOR and MAPK pathways for protein synthesis and cell proliferation; short free-peptide half-life favors brief, localized signaling rather than sustained systemic exposure

Target: IGF-1 receptor (IGF1R); reduced IGFBP-1/IGFBP-3 binding

Research Indications

Growth Hormone SupportMost Effective

Stimulates natural GH release through pituitary signaling pathways

Body CompositionEffective

Associated with increased lean mass and reduced body fat

Recovery & RepairEffective

Supports tissue repair and recovery from exercise or injury

Sleep QualityModerate

Some protocols show improvements in slow-wave and restorative sleep

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Conservative Research Start50 mcgOnce daily (peri-workout)SubQ or IM
Common Research Range50–100 mcgOnce dailySubQ or IM
Upper Community Discussion100–150 mcgOnce daily, short cyclesSubQ or IM

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

Insulin / insulin secretagoguesAvoid
IGF-1 LR3 (redundant IGF-axis load)Caution
HGH / GH secretagoguesMonitor
PEG-MGFCaution
BPC-157Compatible
Blood glucose–lowering medicationsMonitor

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    Remove IGF-1 DES vial from refrigeration and allow to reach room temperature (15–20 minutes)

  2. 2

    Clean vial top with alcohol swab and allow to air dry completely

  3. 3

    Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

  4. 4

    Inject BAC water slowly down the side of the vial — do not aim directly at the powder

  5. 5

    Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

  6. 6

    Allow 2–3 minutes for full dissolution — solution should be clear and colorless

  7. 7

    Draw calculated dose into an insulin syringe for subcutaneous injection

  8. 8

    Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

  9. 9

    Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Improved sleep quality may begin. Mild water retention possible initially.

Week 2–4

Deeper sleep, improved recovery. Appetite may increase slightly.

Week 4–8

Noticeable improvements in body composition, energy, and recovery speed.

Week 8–12

Skin quality improvements, reduced body fat, increased lean mass becoming visible.

Week 12+

Sustained improvements in body composition, strength, and overall vitality.

Side Effects & Safety

  • Hypoglycemia — the primary preclinical safety signal for IGFBP-poor IGF variants; monitor blood glucose closely
  • Symptoms of low blood sugar (shakiness, sweating, confusion) especially peri-workout or when fasted
  • Injection site reactions (redness, bruising, discomfort)
  • Theoretical growth-pathway concerns from strong IGF-1 receptor activation
  • Risk of additive hypoglycemia when combined with insulin or other IGF-axis compounds — avoid casual stacking
  • Human safety is not established — research-only and not FDA-approved

FDA Status & Regulatory Info

Research Only — Preclinical Evidence

IGF-1 DES (des(1-3)IGF-1) is a truncated 67-amino-acid analog of insulin-like growth factor-1 missing the N-terminal Gly-Pro-Glu tripeptide. Reduced IGF-binding protein affinity leaves more free peptide for IGF-1 receptor activation, yielding roughly 2–10× potency vs native IGF-1 in preclinical assays — but a very short ~20–30 minute half-life. Evidence is almost entirely animal/cell literature; not FDA-approved.

Rx Required: No
503A Ban: No
Telehealth: N/A
Full FDA Status Tracker

Frequently Asked Questions

Research purposes only

This page is for educational reference. It is not medical or legal advice. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.